These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12076553)

  • 1. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.
    Suárez PG; Floyd K; Portocarrero J; Alarcón E; Rapiti E; Ramos G; Bonilla C; Sabogal I; Aranda I; Dye C; Raviglione M; Espinal MA
    Lancet; 2002 Jun; 359(9322):1980-9. PubMed ID: 12076553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.
    Mitnick C; Bayona J; Palacios E; Shin S; Furin J; Alcántara F; Sánchez E; Sarria M; Becerra M; Fawzi MC; Kapiga S; Neuberg D; Maguire JH; Kim JY; Farmer P
    N Engl J Med; 2003 Jan; 348(2):119-28. PubMed ID: 12519922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
    Piubello A; Harouna SH; Souleymane MB; Boukary I; Morou S; Daouda M; Hanki Y; Van Deun A
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1188-94. PubMed ID: 25216832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.
    Becerra MC; Appleton SC; Franke MF; Chalco K; Arteaga F; Bayona J; Murray M; Atwood SS; Mitnick CD
    Lancet; 2011 Jan; 377(9760):147-52. PubMed ID: 21145581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
    Floyd K; Hutubessy R; Kliiman K; Centis R; Khurieva N; Jakobowiak W; Danilovits M; Peremitin G; Keshavjee S; Migliori GB
    Eur Respir J; 2012 Jul; 40(1):133-42. PubMed ID: 22362862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R; Hittel N; Schaberg T
    Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
    Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
    Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines.
    Tupasi TE; Gupta R; Quelapio MI; Orillaza RB; Mira NR; Mangubat NV; Belen V; Arnisto N; Macalintal L; Arabit M; Lagahid JY; Espinal M; Floyd K
    PLoS Med; 2006 Sep; 3(9):e352. PubMed ID: 16968123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV; Griffiths UK; Vassall A
    Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
    Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
    Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs.
    Abate G; Miörner H; Ahmed O; Hoffner SE
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):580-4. PubMed ID: 9661826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic.
    Rodriguez M; Monedero I; Caminero JA; Encarnación M; Dominguez Y; Acosta I; Muñoz E; Camilo E; Martinez-Selmo S; de los Santos S; del Granado M; Casals M; Cayla J; Marcelino B
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):520-5. PubMed ID: 23485386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru.
    Chavez Pachas AM; Blank R; Smith Fawzi MC; Bayona J; Becerra MC; Mitnick CD
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):52-8. PubMed ID: 14974746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
    Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.